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Summary
Oligodendroglia support axon survival and function through mechanisms independent of 
myelination and their dysfunction leads to axon degeneration in several diseases. The cause of this 
degeneration has not been determined, but lack of energy metabolites such as glucose or lactate 
has been hypothesized. Lactate is transported exclusively by monocarboxylate transporters, and 
changes to these transporters alter lactate production and utilization. We show the most abundant 
lactate transporter in the CNS, monocarboxylate transporter 1 (MCT1), is highly enriched within 
oligodendroglia and that disruption of this transporter produces axon damage and neuron loss in 
animal and cell culture models. In addition, this same transporter is reduced in patients with, and 
mouse models of, amyotrophic lateral sclerosis (ALS), suggesting a role for oligodendroglial 
MCT1 in pathogenesis. The role of oligodendroglia in axon function and neuron survival has been 
elusive; this study defines a new fundamental mechanism by which oligodendroglia support 
neurons and axons.
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
#Corresponding Author: Jeffrey D. Rothstein MD, PhD, Brain Science Institute, Johns Hopkins University, 855 N Wolfe St./Rangos 
270, Baltimore, MD 21205, USA. Tel: +1 410 614 3846; Fax: +1 410 502-5459, jrothstein@jhmi.edu.
*Authors contributed equally to this work
Author Contributions
All of the authors contributed to the design of the experiments. MCT1 BAC Reporter experiments were designed and performed by 
Youngjin L., L.J., and P-W.Z. MCT-ASO, MCT1i, and human Western blot experiments were designed and performed by B.M.M., 
Yun.L., A.T., Yiting.L., and J.D.R. Lentiviral experiments were designed and performed by Youngjin L., B.M.M., Yun L., and J.D.R. 
The MCT1 heterozygote null mice were produced by S.L., L.P., and P.M, and analyzed by Youngjin L. EM work completed by 
M.H.F., Youngjin L., B.M.M., and J.D.R. Optic nerve lentiviral injections performed by P.N.H. The manuscript and figures were 
prepared by B.M.M. and J.D.R. with input from co-authors.
Competing interests statement: Authors have no competing interests.
HHS Public Access
Author manuscript
Nature. Author manuscript; available in PMC 2013 January 26.
Published in final edited form as:
Nature. 2012 July 26; 487(7408): 443–448. doi:10.1038/nature11314.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Introduction
Oligodendroglia promote rapid conduction of action potentials by ensheathing central 
nervous system (CNS) axons with myelin. Oligodendrocyte diseases, such as multiple 
sclerosis and leukodystrophies, have demonstrated demyelination and axon degeneration at 
autopsy.1,2 Mouse models of oligodendrocyte injury, including proteolipid protein (plp1)-
null mice3 and Cnp1 mutant mice4, demonstrate axon loss without significant 
demyelination, suggesting that oligodendroglia support axon survival through a myelin-
independent mechanism, possibly as a result of insufficient axonal energy support.5 
Myelinated axons are only exposed to extracellular energy substrates at the nodes of 
Ranvier, and therefore may require specialized transport of energy metabolites from 
myelinating oligodendroglia to meet their high metabolic needs. The identity of these 
metabolites is unclear, but our study suggests that lactate may be essential and its transport 
dependent on monocarboxylate transporter 1 (MCT1 or SLC16a1; Supplemental Fig. 1).
MCT1, along with MCT2 and MCT4, transport monocarboxylic acids (i.e., lactate, 
pyruvate, and ketone bodies) and localize to the CNS.6 Neurons express MCT2, and glia 
express both MCT1 and MCT4,7,8 though MCT1 is the dominant glial transporter in the 
brain.9 Recently, MCT1 was localized to oligodendroglia and MCT2 to axons of the corpus 
callosum and cerebellar white matter by immunohistochemistry.10 In vitro astrocytes 
produce lactate through aerobic glycolysis,11,12 and lactate alone can support neurons in the 
absence of glucose, presumably through MCT2 localized to neurons. This hypothetical 
energy transfer was termed the astrocyte-neuron lactate shuttle.13 Support for lactate-based 
neuronal support have come from both in vitro and in vivo paradigms;14,15 however, the 
physiologic role for lactate in the non-stressed, uninjured CNS is largely unknown. We now 
report that oligodendroglia are a significant site of MCT1 expression in the brain and spinal 
cord and are the principal metabolic supplier of lactate to axons and neurons.
Oligodendroglia injury is well established in demyelinating diseases,16 but the supply of 
energy metabolites to axons could be critical in other neurologic diseases, as well. In this 
study, we investigated ALS, a fatal neurologic disease characterized clinically by 
progressive weakness and pathologically by cortical and spinal motoneuron degeneration. 
Although the pathogenesis of motoneuron degeneration is unknown, it is mediated partly by 
surrounding astroglia and microglia.17 A recent study suggests that grey matter 
oligodendroglia may be injured in ALS,18 and we propose that reduced expression of MCTs 
is one mechanism by which oligodendroglia produce neurotoxicity in ALS.
MCT1 mRNA localized to oligodendroglia in vivo
Astrocytes,8,19,20 ependymocytes, endothelial cells,19,21 and recently oligodendroglia10 have 
inconsistently been demonstrated to express MCT1. This variability is due to limitations in 
antibody specificity and/or affinity, along with differences in age and species analysed. To 
overcome this technical challenge, we produced two lines of BAC-MCT1 td-Tomato 
reporter mice (BAC-MCT1) for cellular localization and in vivo expression level of MCT1 
mRNA in the CNS and peripheral organs (Fig. 1 and Supplementary Figs. 2–4). Results are 
shown for the highest expressing line, though cellular localization was identical for the 
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second line (data not shown). Enrichment of MCT1 mRNA was found within fluorescence-
activated cell sorted (FACS) td-Tomato-positive cells (Group b; Fig. 1a) verifying the 
specificity of the reporter. Expression was similar in perinatal mice, though reporter 
expression around blood vessels was increased (data not shown). BAC-MCT1 were crossed 
with BAC-MOBP eGFP (GENSAT) and BAC-GLT1 eGFP reporter mice,22 which express 
eGFP driven by the oligodendrocyte-specific myelin-associated oligodendrocyte protein 
(MOBP) and astrocyte-specific glutamate transporter 1 (GLT1), respectively. MCT1 mRNA 
was almost exclusively localized to oligodendroglia in the brain and spinal cord (Fig. 1 and 
Supplementary Fig. 3), with greater than 70–80% co-localization in spinal cord, cortex, and 
corpus callosum (Fig. 1p). Rare neuronal populations expressed MCT1 (Supplementary Fig. 
4), though none in retinal ganglion cells (Supplementary Fig. 2k) or spinal cord 
motoneurons (Supplementary Fig. 4o,p). Surprisingly, there was virtually no expression of 
MCT1 mRNA within adult CNS astrocytes (Fig. 1 and Supplementary Fig. 3), nor was it 
found in NG2 cells, endothelial cells, or microglia (Fig. 1). The majority of BAC-MCT1-
positive cells co-labelled with an oligodendroglia lineage marker, oligodendrocyte 
transcription factor 2 (Olig2; Fig. 1l),23 while few other CNS cells expressed tdTomato (Fig. 
1p).
MCT1 protein also co-localized with myelinating oligodendroglia, as MCT1 
immunoreactivity co-localized with myelin basic protein and CNPase in rodent and human 
brain (Supplementary Fig. 5). MCT1 protein was closely aligned with axons Supplementary 
Fig. 5h–j), but not astroglia, axonal nodes, or paranodes (Supplementary Fig. 5k–p). In vitro, 
NG2 cells and primary oligodendroglia both expressed tdTomato MCT1 reporter 
(Supplementary Fig. 6a–f), as do primary astrocyte cultures (Supplementary Fig. 6g–l),24 
which may account for the discrepancies in MCT1 localization in the literature.
The cell specificity and enrichment of native MCT1 mRNA was further evaluated by FACS 
and bacterial artificial chromosome translating ribosome affinity purification (BacTRAP) 
techniques. MCT1 mRNA, quantified by real-time RT-PCR of acutely isolated mouse brain 
mRNA from FACS and BacTRAP astrocytes and oligodendroglia, was expressed at 16-fold 
(FACS) and 31-fold (BacTRAP) higher levels in mature oligodendroglia compared to 
astrocytes (Fig. 1q). MCT1 expression (Fig. 1r) and functional lactate transport (Fig. 1s) 
were also detected and enriched in oligodendrocyte tumor cells (i.e., oligodendroglioma) as 
compared to astrocyte tumor cells (i.e., astrocytoma). Although not detectable by either the 
BAC MCT1 td-Tomato reporter mice or immunohistochemistry, FACS and BacTRAP 
experiments suggest that astrocytes express very low levels of MCT1 mRNA in vivo; though 
it is clear that MCT1 expression and lactate transport is much greater in oligodendroglia 
than astrocytes. Astrocytes in vivo express the MCT4 lactate transporter (unpublished 
observation),25,26 suggesting this transporter may play a more important role in astrocytes 
than MCT1.
Neuronal survival in vitro requires MCT1
Similar to in vivo, MCT1 mRNA is primarily localized to oligodendrocyte-lineage cells, 
immunostained with Olig2, in postnatal organotypic spinal cord cultures (Supplementary 
Fig. 7). To investigate whether downregulation or inhibition of MCT1 produces neuron 
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death, organotypic spinal cord cultures were treated with antisense oligonucleotides (ASO) 
or a specific MCT1 transport inhibitor (MCT1i; Supplementary Fig. 7i).27 Following three 
weeks of treatment, only 67% of motoneurons survived in the ASO group (± 6.7 S.E.M., P < 
0.01, Fig. 2a,b) and 66% (± 5.9 S.E.M., P < 0.05, Fig. 2c) in the MCT1i group. Thus, 
genetic or pharmacological reduction of MCT1 led to motoneuron death.
If the function of MCT1 is to export lactate from oligodendroglia and provide energy 
metabolites to neurons, then neurons exposed to glucose-free media or stimuli that increase 
neuronal activity should be particularly vulnerable. Motoneurons in organotypic spinal cord 
slice cultures were resistant to short periods (i.e., 2 hours) of glucose deprivation (GD), 
presumably due to the presence of glycogen stores in astrocytes.28 Simultaneous exposure to 
GD and MCT1i led to concentration-dependent motoneuron loss, as measured by counts of 
neurofilament-containing neurons in the ventral horn (Fig. 2d, P < 0.01), and overall cell 
death, as measured by propidium iodide (PI) uptake (Fig. 2e, P < 0.001). PI uptake occurred 
primarily within neurons (Fig. 2g,i, P < 0.001 and Supplementary Fig. 7) and occasionally 
within Iba-1-positive microglia (Fig. 2i and Supplementary Fig. 7). Much of the PI uptake in 
microglia is likely due to phagocytosing dead cells; however, limited microglia death cannot 
be excluded. Importantly, there was no death of oligodendrocyte-lineage cells or astrocytes 
following treatment with MCT1i and glucose deprivation (Figs. 2h,i and Supplementary Fig. 
7). Other neurons were also vulnerable to treatment with GD and MCT1i since significant PI 
uptake was seen in the dorsal horn of the spinal cord and in organotypic cultures from 
neocortex (Supplementary Fig. 7). MCT1i-GD-induced neurodegeneration was completely 
prevented by supplementing media with 20 mM L-lactate (Fig. 2f, P < 0.01), confirming 
that the toxicity in cultures was due to reduced lactate release from oligodendroglia, not 
blockage of lactate uptake on neurons or oligodendroglia. Cell death was also produced by 
co-treatment of organotypic spinal cord cultures with MCT1i and either glutamate or the 
GABA antagonist, bicuculline, both of which depolarize neurons in slice cultures 
(Supplementary Fig. 8; p< 0.05).29,30 Since glutamate is also a substrate of metabolism, we 
confirmed that cell death was dependent on neuron depolarization by blocking cell death 
with the AMPA/kainate receptor antagonist, CNQX (Supplementary Fig. 8). In summary, 
neurons in vitro are vulnerable to inhibitors of MCT1 lactate transport. Toxicity is 
potentiated by removing glucose or increasing the metabolic activity of neurons and 
prevented by supplying exogenous lactate.
Downregulation of MCT1 in-vivo is motoneuron toxic
To downregulate MCT1 in vivo, we produced a lentivirus that expressed GFP and MCT1 
shRNA driven by the CMV and H1 promoters, respectively (lenti-shRNA). Lenti-shRNA 
downregulated MCT1 protein both in cultured cells and in vivo cervical spinal cord (Fig. 
3a). The amount of downregulation in vivo is underestimated by Western blot since only a 
fraction of oligodendroglia are transfected by virus. Controls included injection of a 
lentivirus expressing only GFP (lenti-GFP) and contralateral injections of virus media. Both 
lentiviruses (lenti-shRNA and -GFP) effectively transduced oligodendroglia and astrocytes 
(Fig. 3b,c). Four weeks following cervical spinal cord injection of lenti-shRNA, 56% (± 5.7 
SEM, n = 10, P < 0.05) of motoneurons near the injection site survived relative to 
contralateral media injection, while lenti-GFP had no significant effect (Fig. 3, P >0.05). In 
Lee et al. Page 4
Nature. Author manuscript; available in PMC 2013 January 26.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
addition, numerous pathologic axonal swellings, immunoreactive for neurofilament 
(SMI32), resulted from lenti-shRNA treatment (Fig. 3g). As expected, motoneuron death in 
lenti-shRNA injected spinal cords produced microglial activation, which was not seen with 
lenti-GFP control (Fig. 3h,i). Thus, subacute downregulation of MCT1 focally in the spinal 
cord is sufficient to produce motoneuron death.
MCT heterozygote null mice develop CNS axonopathy
MCT1 shRNA treatment was neurotoxic and we postulated that reducing expression of 
MCT1 in a null mouse would also produce neurodegeneration. Complete absence of MCT1 
is embryonically lethal, but heterozygote null mice (MCT1+/−), with ~50% reduction in 
MCT1, mature and breed normally with no gross phenotypic abnormalities. The mice 
eventually developed an axonopathy in the brain and spinal cord by 8 months of age, with 
axon swellings visualized by both light and electron microscopy (EM; Fig. 4 and 
Supplementary Fig. 9). Interestingly, axon pathology in these mice is similar to CNPase null 
mice,31 SOD1 transgenic model of ALS,32 and ALS patients.33 Despite the axonopathy and 
activation of astrocytes, microglia, and NG2-positive cells (Fig. 4 and Supplementary Fig. 
9), there was no change in overall myelination in MCT1+/− mice (Supplementary Fig. 9a–f), 
suggesting that the pathology was not secondary to oligodendrocyte injury.
In the optic nerve, a pure sample of CNS axons whose function is partly dependent on 
lactate,34 large and intermediate sized degenerating axons were observed in MCT1+/− mice 
(Fig. 4o). Overall, 1.74 ± .06 % of optic nerve axons from MCT1+/− mice showed 
morphologic features of degeneration, including swellings, enlarged mitochondria and 
reduced axon diameter, which were not seen in age-matched littermate control mice (Fig. 4 
and Supplementary Fig. 9). Importantly, oligodendrocyte morphology (Fig. 4p) and number 
were not changed, nor was myelination as represented by normal g-ratios (Fig. 4r) and intact 
myelin in non-degenerating axons (Supplementary Fig. 9), again suggesting that axonal 
degeneration was not due to oligodendrocyte damage or demyelination. Thus, despite only 
having a partial reduction in MCT1 expression (Supplementary Fig. 9j), adult MCT1+/− 
mice demonstrate widespread CNS axonopathy. Given the low percentage of axons affected, 
it is not surprising that this axonopathy did not produce a behavioral phenotype, loss of 
motoneurons (Fig. 4s), or obvious injury to retinal ganglion cells (Supplementary Fig. 9t,u) 
in MCT1+/− mice. In summary, MCT1+/− mice develop axon degeneration in the CNS 
without demyelination or oligodendrocyte injury, suggesting that MCT1 is critical for the 
normal function of CNS axons through a myelin-independent mechanism.
Oligodendrocyte-specific MCT1 loss causes axonopathy
Though MCT1 is primarily expressed within oligodendroglia in the CNS, it is not exclusive 
to oligodendroglia and thus we cannot exclude that the axon degeneration seen in MCT1+/− 
mice is due to downregulating MCT1 in other cell types. To investigate this, we produced 
two lentiviral constructs that downregulate MCT1 selectively in oligodendroglia through 
different mechanisms. First, lentiviral constructs were produced that expressed either the 
same MCT1 shRNA used in Figure 3 and GFP (Lenti-MBP-shRNA) or GFP alone (Lenti-
MBP-GFP) driven by the MBP promoter. Lenti-MBP-shRNA downregulated MCT1 protein 
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in the optic nerve (Fig. 5a,b) despite transfecting only a small segment of nerve (Fig. 5c,d). 
Transfection was selective for oligodendrocyte-lineage cells, as seen by co-localization of 
all GFP-labelled cells with Olig2 (Fig. 5e,g; arrows) and not astroglia (Fig. 5c,d). At the 
injection site, there were a few pathologically enlarged SMI32-positive axons in Lenti-
MBP-GFP injected optic nerves due to nerve trauma (Fig. 5f; arrowheads), but 
dramatically more in optic nerves injected with Lenti-MBP-shRNA (Fig. 5h; arrowheads). 
Distal to the injection, there were increased degenerating axons, both myelin ovoids 
(arrows) and “dark axons” (asterisks), in Lenti-MBP-shRNA injected optic nerve compared 
to Lenti-MBP-GFP injected (Fig. 5i–l). Restricted penetration of the lentivirus into the nerve 
led to some variability in axon degeneration. Nevertheless, there was a significant increase 
in the number of degenerating fibers in optic nerves injected with Lenti-MBP-shRNA 
compared to Lenti-MBP-GFP (Fig. 5p,q; n=4 nerves, p<0.05).
We also developed a tamoxifen inducible cre-dependent lentivirus expressing MCT1 
shRNA and produced oligodendrocyte-specific MCT1 knockdown by injecting virus into 
the corpus callosum of PLP-CreER transgenic mice under inducible control by tamoxifen 
(Supplementary Fig. 10a).35,36 Viral transfection of corpus callosum oligodendroglia was 
confirmed in control mice by co-localization of GFP with both CC-1 and MCT1 reporter 
(Supplementary Fig. 10b–g; arrowheads). In tamoxifen-treated PLP-Cre mice, the GFP 
reporter was excised in oligodendroglia, so specific viral localization of GFP to 
oligodendroglia is generally not visualized. In the PLP-Cre mice, there was clear axonal 
degeneration near the injection site, as demonstrated by both SMI32-immunoreactive axon 
swellings (Supplementary Fig. 14k–m; boxed areas) and axonal beading in GFP labelled 
axons (Supplementary Fig. 14n), that was not observed when the identical virus was injected 
into wild type mice (Supplementary Fig. 14h–j). Thus, in vivo oligodendrocyte-specific 
downregulation of MCT1 in both the optic nerve and corpus callosum was capable of 
producing axon degeneration. Overall these studies confirm that oligodendrocyte MCT1 is 
critical for axon survival as loss of lactate transport from oligodendroglia to axons causes 
axon degeneration in both viral knockdown experiments and MCT1+/− mice.
MCT1 expression reduced in ALS
Recent studies suggest oligodendroglia or their precursors may be injured in mutant SOD1 
transgenic mice.18 We hypothesized that reduced ability of gray and white matter 
oligodendroglia to support motoneurons, by altered MCT1 expression, may contribute to 
ALS pathogenesis as seen in our in vitro and in vivo studies described above. We 
investigated the expression level of MCTs and the MCT-associated protein CD147 in 
affected (i.e., motor cortex) and unaffected (i.e., frontal cortex) regions from ALS and non-
ALS patients. In addition, we investigated MCT1 reporter activity in the spinal cord of 
SOD1G93A transgenic mice, a commonly used model of ALS that had been crossed with 
BAC-MCT1 td-Tomato reporter mice. Motor cortex of ALS patients showed a greater than 
50% decline in MCT1 and MCT4 (p<0.01 and p<0.001, respectively) compared to gender 
and age-matched control patients (Fig. 6 and Supplementary Table 1). This reduction was 
not seen in unaffected frontal cortex, nor was it seen for CD147 (also known as basigin), an 
accessory glycoprotein that increases localization of MCT1 and MCT4 to the plasma 
membrane (Full blots available in Supplementary Figs. 12 and 13).37 Oligodendroglia were 
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still present in the cortical samples since there was no significant alteration in CNPase (Fig. 
6a,b), though it is possible the oligodendroglia were immature.
In addition to patients with ALS, downregulation of MCT1 mRNA was also seen in the 
spinal cords of early symptomatic (Supplementary Fig. 11) and endstage (Fig. 6) SOD1G93A 
transgenic mice. SOD1G93A transgenic mice were mated to MCT1-BAC mice, and MCT1 
mRNA expression evaluated by tdTomato fluorescence. In SOD1G93A transgenic mice, 
MCT1 reporter continued to exclusively label oligodendroglia throughout the brain, though 
there was a dramatic reduction in MCT1 expression in the ventral horn grey matter (outlined 
by dashes; Fig. 6d,e) as compared to age-matched control mice (Fig. 6f,g). Reduced MCT1 
reporter expression was not due to less oligodendroglia, since CC-1-positive oligodendroglia 
were preserved, though again CC-1 immunoreactivity may not be labelling fully mature 
oligodendroglia (Fig. 6e). Taken together, these results suggest that alterations in 
oligodendrocyte MCT1 may contribute to motoneuron degeneration in ALS, and provide a 
human disease in which downregulation of MCT1 is associated with neurodegeneration.
Discussion
Our results suggest that oligodendroglia support of axons, through MCT1 based transport of 
lactate (or pyruvate), is critical for maintaining axon function and neuron survival and 
appears to be a fundamental property of oligodendroglia. Disruption of MCT1 could 
hypothetically cause either reduced lactate export out of, or import into, oligodendroglia 
since the direction of transport is determined by the relative intra- and extra-cellular 
concentrations of lactate and hydrogen ions.6 Our results suggest primarily disruption of 
lactate export. First, exogenous lactate completely prevents cell loss in organotypic cultures 
by compensating for reduced lactate export. Second, oligodendroglia do not degenerate in 
MCT1+/− mice or when exposed to MCT1 inhibitor and glucose deprivation in organotypic 
spinal cord cultures. Third, our study and others 10 demonstrate that MCT1 is predominantly 
localized to the myelin sheath around CNS axons, as expected for a transporter from 
oligodendroglia to axons. Taken together, our results suggest that MCT1-regulated lactate 
export from oligodendroglia is a critical component of the local energy supply to axons and 
the disruption of this transport leads to axon dysfunction and ultimately neuron 
degeneration. Oligodendrocyte support of axons was also suggested by a recent paper that 
found elevated brain lactate in transgenic mice with a selective deficit in oligodendroglia 
mitochondrial function.5 Of course, lactate may also be imported into oligodendroglia and 
contribute to the production of myelin, as has been shown in dissociated38 and cortical slice 
cultures,39 but attenuation of MCT1 does not appear to cause neuron or axon degeneration 
through this mechanism.
Our results contribute to the emerging data that oligodendroglia are implicated in ALS. 
Spinal cord ventral grey matter oligodendrocyte precursor cells dramatically replicate in 
ALS mouse models,18 possibly in response to oligodendroglial injury (unpublished data), 
and cytoplasmic inclusion are found in human ALS oligodendroglia.40 We found that MCT1 
is reduced in affected brain regions from ALS patients and the ventral horn of the spinal 
cord in mutant SOD1 transgenic mice. These changes could reflect downregulation of the 
transporter within intact oligodendroglia, or perhaps death of oligodendroglia and 
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replacement with immature oligodendroglia. Newly generated oligodendroglia, labelled with 
CC-1, do not contain MCT1 (Fig. 6) and therefore would be unable to supply energy 
metabolites to axons, leading to axon injury and neuron loss. We hypothesize that this 
mechanism contributes to motoneuron degeneration in ALS. Future experiments will 
investigate this specifically by determining if MCT1 downregulation is specific for ALS and 
whether MCT1 upregulation or transplantation of oligodendroglia can prolong survival in 
ALS mouse models.
Methods Summary
BAC-MCT1 mice were developed and MCT1 expression localized to specific cells by 
crossing with cell specific reporter lines, immunostaining for cell-specific markers, or 
isolating mRNA by FACS and BacTRAP. Critical function of oligodendrocyte MCT1 was 
evaluated in vitro in organotypic spinal cord cultures, in vivo in MCT1+/− mice or wild-type 
mice injected with lentiviral vectors. Neuronal toxicity, measured by loss of neurofilament-
containing neurons and incorporation of PI, was provoked in organotypic cultures by 
treating with ASO or MCT1i. MCT1+/− mice were evaluated by histology, 
immunohistochemistry, and EM, and compared to littermate controls. For lentiviral 
experiments, MCT1shRNA was subcloned into lentivirus plasmid along with 3 different 
promoters (i.e., H1, myelin basic protein (MBP), and Cre-dependent H1). H1-MCT1shRNA 
lentivirus was injected into the spinal cord of C57Bl6 wild-type mice and motoneurons in 
the vicinity of virus were counted and compared to control virus injections. MBP-
MCT1shRNA was injected into the optic nerve of Sprague –Dawley rats and degenerating 
axons quantified by EM and compared to the contralateral optic nerve injected with control 
virus. Cre-dependent H1-MCT1shRNA lentivirus was injected into the corpus callosum of 
PLP-Cre mice and axon pathology by non-phosphorylated neurofilament immunostaining. 
Finally, MCT1 expression was evaluated by Western blots of cortex from ALS patients and 
non-ALS controls; and MCT1 expression in SOD1G93A transgenic mice, obtained from 
Jackson laboratories, was evaluating by crossing these mice to MCT1 BAC reporter mice.
METHODS
Development of MCT1 BAC Reporter and MCT1 overexpressor mice
BAC MCT1 tdTomato reporter mice were produced as described previously.22 The BAC 
construct was modified to include the entire 19.8kb MCT1 gene plus 50kb upstream of the 
first exon and 132.2kb downstream of the last exon (Supplementary Fig. 2a). Founder lines 
were identified by PCR (primer pair was 5′-CGAGGAGGTCATCAAAGAGT-3′ and 5′-
AGAACTTGAGGTGGTCCATC-3′) and also by tdTomato fluorescence within red blood 
cells. Two expression lines were produced and backcrossed with B6 or C57BL/6 wild-type 
mice. To produce MCT1 overexpressor mice, the promoter for the astrocyte-specific gene, 
glial fibrillary acidic protein (GFAP), was used to drive MCT-1 overexpression specifically 
in astrocytes,41 was inserted between the GFAP promoter sequence and an internal 
ribosomal entry site (IRES)-eGFP sequence, resulting in expression of MCT-1 and eGFP 
together in astrocytes. Six founder lines were generated, of which five expressed MCT-1 and 
eGFP within CNS astrocytes.
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Generation of lines coexpressing MCT1 BAC reporter and other transgenes
BAC GLT1 eGFP,22 BAC MOBP eGFP (GENSAT), PLP-eGFP (Jackson laboratory), PLP-
CreER (Jackson laboratory), CNP-EGFP/Rpl10a (Jackson Laboratory), Aldh1L1 
(GENSAT), Thy-I YFP (Jackson laboratory), and SOD1 G93A transgenic mice (Jackson 
laboratory) were crossed with BAC MCT1 reporter mice to establish double transgenic 
mice.
Fluorescent activated cell sorting (FACS), real-time RT PCR, RT-PCR, and BacTRAP
Brains from 1 month old BAC MCT1 tdTomato reporter mice were prepared as described 
previously.42 Cells were sorted into three groups with a MoFlo MLS high speed cell sorter 
(Beckman coulter) running Summit version 4.3 software in the FACS core at The Johns 
Hopkins University. Total RNA prepared from sorted cells and tissue using Absolutely RNA 
Miniprep Kit (Stratagene, La Jolla, CA) was converted to cDNA using cDNA synthesis kit 
(Applied Biosystems, Foster city, CA). PCR for MCT1 or GAPDH (control) was completed 
using the following primer pairs, respectively: (5′-AAAATGCCACCTGCGATTG GA-3′ 
and 5′-GCCTGATTAAGTGGAGCCAGG-3′), or (5′-TTGCCATCAATGACCCCTTCA -3′ 
and 5′-CGCCCCACTTGATTTTGGA -3′). TaqMan premade gene-specific probes and 
18srRNA (as a control) were used for real time RT-PCR. For the FACS isolation of 
oligodendroglia and astrocytes in the brains, young adult BAC MOBP eGFP- and BAC 
GLT1 eGFP- mice (1–2 month) were used as described previously.42 For affinity 
purification of polysomal mRNAs from oligodendroglia and astrocytes in the brain, adult 
CNP BacTRAP (translating ribosome affinity purification)- and ALDH BacTRAP- mice 
were used, respectively, as described previously.43
Primary antibodies for Western blots and immunohistochemistry
Detailed protocols for Western blots and immunohistochemistry are described below. The 
following primary antibodies were used for Western blots: MCT1-human (AbGent; 1:75), 
MCT1-mouse (Santa Cruz; 1:50), MCT4 (Millipore; 1:400), CD147 (Novus Biologicals; 
1:500), CNPase (Millipore; 1:1000), Connexin 43 (Millipore; 1: 500), and β-actin 
(Millipore; 1:1000). The following primary antibodies were used for immunofluorescence: 
mouse MCT-1 (Santa Cruz; 1:50), human MCT-1 (Santa Cruz; 1:50), Olig2 (Millipore; 
1:500), CC-1 (Calbiochem; 1:50), CNPase (Millipore; 1:250), MBP (Covance; 1:250), 
PDGFRα (BD Pharmingen; 1:100), NG2 (Millipore; 1:100), GFAP (Dako; 1:2000), Iba1 
(Wako; 1:250), NeuN (Millipore; 1:250), SMI-32 (Covance; 1:1000) Ubiquitin (Millipore; 
1:250), Caspr (from Bergles’ lab; 1:1500), Nav1.6 (from Bergles’ lab; 1:100), DsRed 
(Clontech;1:250), Tuj1 (Millipore, 1:1000), NeuN (Millipore (1:1000), ALDH1L1 
(Neuromab/UC Davis, 1:10), and Iba1 (Wako, 1:500).
Lactate uptake assay in oligodendroglioma and astrocytoma cell lines
MO3.13 oligodendroglioma and U87 astrocytoma cell lines are cultured as described in 
previous reports.44,45 Lactate uptake assay was completedas described previously46 with 
only small modifications. In brief, cells were incubated with 0.5 μCi/mL L-[1-14C] lactic 
acid (Perkin-Elmer, Boston MA, USA) in HEPES-buffered, Earl’s balanced salt solution 
(HEBSS) buffer, pH 6.0, containing150mM NaCl, 5mM KCl, 1mM KH2PO4, 0.2mM 
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CaCl2.2H2O, 3.3mM MOPS, 10mM HEPES, 1mM MgSO4.7H2O. After incubation, uptake 
was stopped by quickly chilling the cultures to 4 °C. Cells were washedwith ice-cold 
HEPES buffer, homogenized in 0.1N aOH and 0.1% Triton X100, and centrifuged at 
13000rpm for 10 minutes. Radioactivity was measured byscintillation counting and 
corrected by protein amount.
Immunohistochemistry, histology, light and electron microscopy
Mice were anesthetized with isoflurane/oxygen and perfused transcardially with 1X PBS 
followed by 4% paraformaldehyde in PBS (for light microscopy [LM]) or 4% 
paraformaldehyde/2.5 % glutaraldehyde in PBS (for electron microscopy [EM]), tissue 
collected, and either cryoprotected in graded concentrations of sucrose and sectioned at 20 
μm on a Leica CM1900 cryostat (for LM) or embedded in Epon resin after postfixing in 
osmium tetroxide (for EM).
To assess neuropathology by light microscopy, tissue sections were stained with 
hematoxylin and eosin (H&E), Eriochrome staining, Bielschowsky silver staining, or 
immunohistochemistry (IHC). For lectin staining of endothelial cells, biotinylated 
Lycopersicon esculentum lectin (1:200 dilution; B-1175; Vector Laboratories, Burlingame, 
CA, USA) was incubated with sections for 1 hour. As a secondary antibody, sections were 
incubated in Streptavidin-488 (1:100 dilution; B-1175; Vector Laboratories, Burlingame, 
CA, USA). For IHC of MCT1, tissue slices were pre-treated with sodium citrate buffer 
(10mM Sodium Citrate, 0.05% Tween 20, pH 6.0) for antigen retrieval (other primary 
antibodies did not require antigen retrieval) prior to 1 hour incubation at room temperature 
in blocking buffer (0.3% BSA, 5% Skim milk, and 0.3% Triton-X 100 in PBS). Primary 
antibodies were incubated overnight at 4°C, washed and then incubated for 2 hours at room 
temperature in anti-mouse or anti-rabbit IgG Alexa-fluor secondary antibodies (Invitrogen; 
1:200). Photomicrographs were taken on Zeiss LSM510 Meta confocal microscopy or Zeiss 
Image Z1 fluorescent microscopy. Co-labeled cells with either immunostaining or transgenic 
reporters were manually counted in Axiovision from digital images taken by fluorescent 
microscopy. For EM, 1 mm thick sections were stained for toluidine blue and examined 
under light microscopy with 100X oil-immersion objective. 70 nm thin sections were 
obtained and stained for citrate/uranyl acetate. For quantification of axon degeneration in the 
optic nerves of MCT1 heterozygous mice and mice treated with lenti-MBP-shRNA, 3 and 
10 7000x electron micrographs, respectively, were acquired for each optic nerve using a 
Zeiss Libra transmission electron microscope. Total number of axons and degenerating 
axons, as defined by degenerating myelin or dark axons, on each electron micrograph were 
counted and percentage axonal degeneration calculated. All quantification was completed by 
an investigator blinded to the genotype or treatment group.
Production of cell cultures
Oligodendrocyte cultures were produced from PND 2–3 mouse cortical tissues of PLP eGFP 
× NG2-tdTomato double transgenic mice. In brief, oligodendrocyte progenitor cells (OPC) 
were isolated by FACS and maintained in OPC culture medium (SATO medium containing 
PDGFα) for 4 days. OPC were further differentiated into mature oligodendroglia in the 
differentiation media (SATO media containing T3 without PDGFα).
Lee et al. Page 10
Nature. Author manuscript; available in PMC 2013 January 26.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Primary astrocyte cultures were produced from PND 2–3 mouse pups. Cortices were 
dissected out and dissociated with papain and subsequently cultured on collagen-coated T75 
flask in DMEM containing 10 % fetal bovine serum (FBS). At DIV14 astroglial cells were 
seeded into collagen-coated 6-well plates at a concentration of 7×105 cells/well.
Organotypic or cortical spinal cord cultures were produced from PND 7 Sprague-Dawley rat 
pups or MCT1 tdTomato reporter mice, as described previously.47
Anti-sense oligonucleotides or MCT1i treatment in organotypic spinal cord cultures
One week after plating organotypic spinal cord cultures, 5 μM MCT1 ASO (IDT) or various 
doses of MCT1i was added to media for 3 weeks. Sections were either visualized with 
propidium iodide (PI, 7.5μM, 2 hrs, Sigma) or fixed with 4% paraformaldehyde, and 
immunostained with the neuronal marker SMI-32 (Covance, 1:1000). Large, ventral horn 
SMI-32-positive neurons were counted by an investigator blinded to the treatment condition.
MCT1i and glucose deprivation in organotypic spinal cord cultures
Two weeks after collection, cultures were pre-treated with MCT1i27 or DMSO for 24 hrs, 
incubated in propidium iodide for 2 hours, and then photographed on a Nikon 
epifluorescence scope (Pre-treatment). Sections were then washed, incubated with glucose-
free or normal buffer ± MCT1i for 2 hrs, allowed to recover for 2 hrs, re-incubated with PI 
for 2 hours, and photographed images quantified by fluorescent intensity (Post-treatment). 
To examine motoneuron loss, sections were returned to normal media for two weeks, fixed 
in 4% paraformaldehyde, and immunostained with SMI-32 (Covance, 1:1000). To study 
cellular localization of PI, sections were immediately fixed in 4% paraformaldehyde and 
then processed for immunocytochemistry with primary antibodies. Secondary antibodies 
used for detection were AlexaFluor 488-conjugated goat anti-rabbit, anti-mouse, or anti-
chicken antibodies (Invitrogen, 1:1000).
Organotypic spinal cord cultures treated with bicuculline or glutamate
For bicuculline (BIC) experiment, spinal cord slice cultures (2 weeks post-culture) were 
treated with 100uM BIC (or vehicle) in the presence or absence of 1mM MCT1i for 3 days. 
To measure cell death, cultures were incubated with PI and then photographed on a Nikon 
epifluorescence scope. For glutamate experiment, spinal cord cultures were incubated with 
MCT1i (or DMSO vehicle for controls) for 24 hours, followed by media with or without 
250uM glutamate buffer for 60 minute. PI staining was performed before and after the 
glutamate treatment to visualize dead cells. For quantification, fluorescent intensities of pre-
treatment sections measured by Image J software for the dorsal horn in BIC treated sections, 
and total spinal cord in glutamate treated sections, were subtracted from post-treatment 
sections. All values were normalized to untreated control sections.
Production of lentiviral constructs
Based on pre-designed ON-TARGETplus SMARTPool siRNA sequences (Dharmacon), 
DNA oligos that contain MCT1-shRNA sequences were synthesized and directly subcloned 
into pSuper vector (Oligoengine, Inc.). The sense and antisense oligo sequences for the most 
efficient MCT1-shRNA were as follows: 5′-GATCCCC 
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GTATCATGCTTTACGATTATTCAAGAGATAATCGTAAAGCATGATACTTTTTTC-3
′ 5′-
TCGAGAAAAAAGTATCATGCTTTACGATTATCTCTTGAATAATCGTAAAGCATG
ATACGGG-3′ DNA fragments spanning the H-1 promoter and the shRNA sequences in 
pSuper construct were amplified by PCR and subcloned into FUGW-CMV to produce 
Lenti-shRNA. Fragments spanning MBP promoter, shRNA, and IRES-EGFP sequences 
were subcloned into FUGW-CMV to produce Lenti-MBP-shRNA. MCT1 shRNA was 
subcloned into the HpaI and XhoI restriction sites of pSico (Addgene) to produce Cre-
inducible lentivirus. Lentiviral constucts, including control GFP constructs, were produced 
in HEK 293 T cells using the FUGW-CMV/Δ8.9/VSVG system.
MCT1-shRNA Lentivirus injected into spinal cord
Unilateral injections of LV-MCT1shRNA (n = 10) or LV-GFP (n = 8) were performed in 
C57BL6 wild-type mice at 100 days-of-age at C4, C5, and C6, delivering 1.7 × 105 PFU for 
LV-GFP or 1.8 × 105 PFU for LV-MCT1shRNA per mouse. Briefly, the transverse 
processes of C4 to C6 were removed, the dura removed, and three 1 μl injections of 
lentivirus or media were injected with a 34 gauge Hamilton syringe needle. Animals were 
sacrificed after 4 weeks by transcardial perfusion with 4% paraformaldehyde. Spinal cord 
sections were cryoprotected, sectioned on a cryostat, and immunostained for neurofilaments 
(SMI-32), oligodendrocyte-lineage cells (Olig2), microglia (Iba1), or astrocytes (GFAP), as 
described above. Large (diameter greater than 20 um) neurofilament-containing neurons in 
the ventral spinal cord were counted from every third section that localized GFP to the 
ventral horns on both the virus- and media-injected halves of the spinal cord (mean number 
of sections counted 11.9 for shRNA group and 12 for GFP group). For each animal, the 
mean number of motoneurons per section from the virus-injected spinal cord hemisection 
was divided by the mean number of motoneurons per section from the contralateral media-
injected motor neurons per section.
Generation of MCT1 heterozygote null mice
MCT1 heterozygote null mice were generated by targeted homologous recombination to 
replace a 640 base pair sequence of the MCT1 gene starting at the translation initiation 
codon and containing exon 1 as well as part of the first intron with the LacZ gene sequence 
fused with a neomycin (Neo) resistance gene sequence and put in frame with the MCT1 
promoter (S. Lengacher et al., manuscript in preparation). Successful recombination event 
and proper insertion of the LacZ/Neo sequence in the targeted locus was controlled by 
Southern blot on DNA from embryonic stem cells previously electroporated with the 
targeted vector and selected with gancyclovir and G418. Genotyping of animals was 
performed by PCR with appropriate set of primers.
MCT1 shRNA driven by MBP promoter injected into rat optic nerves
Sixty day old Sprague Dawley rats were anesthetized with 2 % isofluorane, an incision 
placed in the scalp overlying the orbital ridge, the skin overlying the orbital ridge retracted, 
and a conjunctival suture placed to provide traction to the globe. The optic nerve was 
localized, a window cut in the overlying dura, the nerve pierced with a pulled micropipette, 
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and each nerve infused with 3 μl of either lenti-MBP-shRNA or lenti-MBP-GFP (2.4 × 1011 
virus particles (VP)/ml). After 4 weeks, the rats were transcardially perfused with 4% 
paraformaldehyde and the optic nerves from the globe to the optic chiasm carefully 
dissected. The optic nerve near the injection site was post-fixed in 4% paraformaldeyde, 
cryoprotected in 25% sucrose and cut on a cryostat. These nerve segments were later 
immunostained with Olig2, GFAP, and SMI32. Optic nerve distal to the injection was post-
fixed in 4% paraformaldehyde/2.5% glutaraldehyde for 3 days and then processed for EM as 
described above.
Cre-dependent MCT1 shRNA Lentivirus injected into corpus callosum
Cre-inducible MCT1 shRNA lentivirus was injected bilaterally into the corpus callosum of 
PLP-CreER,36 MCT1 tdTomato reporter, and wild-type mice at approximately 60 days of 
age. Mice were anesthetized with ketamine and xylazine, placed in a stereotaxic device, and 
the corpus callosum injected bilaterally with 2 μl lentivirus (2.6 × 1011 VP/ml), as 
previously described.48 After 1 week, mice were injected intraperitoneally with 1 mg 
tamoxifen for 5 consecutive days to induce Cre recombination of nucleus-integrated virus. 
Mice were sacrificed 4 weeks later by transcardial perfusion with 4% paraformaldehyde. 
Sections were cryoprotected, sectioned on a cryostat, and immunostained for neurofilaments 
(SMI-32) and green fluorescent protein (GFP), as described above.
Western blotting of human autopsy samples, primary cells and mouse tissues
Autopsy samples were obtained from the Johns Hopkins University Brain Resource Center 
and the Johns Hopkins ALS Tissue Bank. Human or mouse samples were homogenized in 
TBS with 0.1% SDS, 1% triton and 10% glycerol, primary cultures were lysed as described 
previously.49 Western blotting and densitometry was performed using the enhanced 
chemilluminescence (ECL) system (GE Healthcare) and NIH Image J.
Statistics
In-vitro ASO and MCT1i experiments were analyzed using one-way ANOVA followed by 
Tukey-Kramer post hoc test. Western blots, real-time RT PCR, and in-vivo LV-
MCT1shRNA quantifications were analyzed using unpaired Student’s t-tests. Quantification 
of axon degeneration in lentivirus injections of optic nerve was evaluated with a Mann 
Whitney test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MCT1 expressed primarily within oligodendroglia in the CNS
(a) Histogram and rtPCR for MCT1 mRNA from FAC sorted cells with (b) or without (a) 
tdTomato expression. (b–e) Corpus callosum of tdTomato MCT1 reporter mice crossed with 
BAC-MOBP eGFP (b,c) or BAC-GLT1 eGFP (d,e) mice. (f–i) Spinal cord of tdTomato 
MCT1 reporter mice crossed with BAC-MOBP eGFP (f,g) or BAC-GLT1 eGFP (h,i) mice 
(Scale bars = 50 and 14 μm for low and high power, respectively). (j–o) TdTomato MCT1 
reporter mouse brain immunostained with cell-specific markers (scale bars = 12.5 μm, 
except 50 μm for lectin). (p) Percentage of tdTomato cells co-labelled with CNS cell 
markers in the spinal cord (blue), cortex (red), and corpus callosum (green). (q,r) Real-time 
rtPCR of MCT1 mRNA isolated from oligodendroglia and astroglia by FACS and 
BacTRAP techniques (q; means of 4 replicates) and human oligodendroglioma (M03.13) 
and astrocytoma (U87) cell lines (r). (s) Lactate transport and blockade by selective MCT1 
inhibitor in oligodendroglioma and astrocytoma.
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Figure 2. MCT1 required for neuronal survival in vitro.
(a–d) Photomicrograph (a) and quantification of motoneurons in spinal cord slice cultures 
treated with media only (Ctrl), MCT1 sense oligonucleotides (Sense), or MCT1 antisense 
oligonucleotides (ASO) for 3 weeks (b; n ≥ 55 sections per group), following 3 weeks 
treatment with MCT1i (c; n ≥ 27 sections per group), or 2 hrs of glucose deprivation (GD) ± 
MCT1i (d; n ≥ 30 sections per group). (e,f) Propidium iodide (PI) uptake in slice cultures 
treated with 2 hrs GD + MCT1i (e; n ≥ 10 sections per group) or 2 hrs GD, ± MCT1i, ± 20 
mM lactate (f; n = 15 for all groups). (g,h) PI uptake in slices treated with GD + MCT1i 
labelled with neuronal (g; co-localized cells marked with arrowheads) or oligodendroglia (h) 
marker. (i) Percentage of PI-labelled cells co-localizing cell-specific markers (n 10 sections 
per group, Error bars = ± S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 3. Lentiviral MCT1 shRNA is toxic to motoneurons
(a) Lenti-shRNA (shRNA) downregulates MCT1 in primary astrocyte cultures and in vivo 
compared to untreated (Con) or lenti-GFP (GFP). (b,c) Olig2 (b) and glial fibrillary acidic 
protein (c; GFAP) in lenti-GFP injected spinal cords. (d–f) Non-phosphorylated 
neurofilament (SMI-32) (red) in spinal cords injected with media (d), Lenti-GFP (e), or 
Lenti-MCT1 shRNA (f, arrows indicate motoneurons). (g) SMI-32 labels aberrant axonal 
swellings in lenti-shRNA injected spinal cords. (h,i) Iba1 positive microglia in spinal cords 
injected with lenti-GFP (h) and lenti-MCT1 shRNA (i). (j) Quantification of cervical spinal 
motoneurons injected with lenti-GFP (n = 8) or lenti-MCT1 shRNA (n = 10), relative to 
contralateral media injection (Scale bars = 50 μm. Error bars = ± S.E.M. *p < 0.05).
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Figure 4. MCT1 heterozygote null mice develop widespread axonopathy
(a–d) Spinal cords of wild-type (WT) and MCT1+/− mice (HET) immunostained for non-
phosporylated neurofilament (SMI-32) (a,b), silver stained (c), or immunostained for 
ubiquitin (d; Scale bars = 20 um). (e) Electron microscopy of axonal spheroid in spinal cord 
(scale bar = 2 μm). (f–h) Optic nerves of WT and HET mice immunostained for SMI-32 
(f,g) or silver stained (h; scale bars = 20 um). (i–n) GFAP (i.l), Iba-1 (j,m), and NG2 (k,n) 
in WT (i–k) and HET mice (l–n ; Scale bars = 50 um). (o,p) Degenerating axon (o; 
indicated by arrow, scale bar = 2 μm) and intact oligodendrocyte (p; scale bar = 6 μm) in 
optic nerve. (q,r) Axon diameter (q) and g ratio (r) in HET (green line/dots ; n=158) and 
WT (red line/dots ; n=78) mice. (s) Distended mitochondrion (astrerisk) in HET optic 
nerve. (t) Number of spinal motorneurons per section from WT and HET mice.
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Figure 5. Selective downregulation of MCT1 in oligodendroglia produces axonal injury
(a,b) Western blot of optic nerves injected with lentivirus expressing MBP-GFP (G) or 
MBP-MCT1shRNA (S). (c,d) Glial fibrillary acidic protein (GFAP) immunoreactivity in 
GFP-expressing (GFP) and MCT1shRNA-GFP expressing (shRNA) viruses (scale bars = 
100 μm). (e,f) GFP and shRNA viruses co-localize exclusively with Olig2 (scale bars = 50 
μm). (g,h) Axon swellings (arrowheads) labelled with SMI-32 following injection of GFP 
(g) and shRNA (h) viruses (scale bars = 20 μm). (i–l) Low (i,k ; scale bars = 1 μm) and high 
(j,l; scale bars = 0.5 μm) magnification EM photomicrographs following injection of GFP 
and shRNA viruses (arrows indicate myelin ovoids and asterisks indicate dark 
degenerating axons). (m,n) Mean number (m ; n=4 nerves/group) and scatterplot (n ; n=40 
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fields/group) of degenerative axons per EM field in GFP- and shRNA-injected optic nerves 
(*p<0.05, ***p<0.001).
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Figure 6. MCT1 reduced in ALS patients and SOD1G93A mice
(a) Immunoblots of MCT1 and myelin related proteins from sporadic ALS (sALS) and non-
ALS patients. (b– c) (N ≥ 8 for ALS patients and ≥ 6 for non-ALS patients). (d–g) 
Immunofluorescence of MCT1 reporter alone (d,f) and double-labelled (red) with CC-1 
(e,g; green) in endstage SOD1G93A transgenic mice (d,e) and littermate controls (f,g; scale 
bars = 100 μm). Dashed lines delineate boundary of ventral horn gray matter.
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